Limba
|
Savolitinib (Volitinib, AZD6094, HMPL-504) is a novel, potent, and selective METinhibitor currently in clinical development in various indications, including PRCC. The IC50values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.
Price | 1.658,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Savolitinib (Volitinib, AZD6094, HMPL-504) is a novel, potent, and selective METinhibitor currently in clinical development in various indications, including PRCC. The IC50values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase. |